Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement
|
EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Agreement
Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement Martinsried (Munich), Germany, May 12, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced the signing of a research and option agreement for a scientific and strategic collaboration with one of Curie.Bio’s portfolio companies. Under the agreement, Secarna will leverage its commercially validated OligoCreator® platform to design and develop oligonucleotide candidates against an undisclosed target, forging an alliance to accelerate the discovery of novel oligonucleotide therapies. In return, Secarna will receive a technology access fee, research funding, and warrants to purchase shares in the portfolio company upon achievement of predefined success milestones. Secarna’s AI-empowered OligoCreator® platform seamlessly integrates diverse delivery technologies as well as proprietary safety and efficacy testing systems to identify and characterize oligonucleotide therapeutics with exceptional speed, safety, and efficacy – strengthening its position as a pivotal tool in transforming previously untreatable conditions into treatable ones and profoundly shaping the future of medicine. "Our AI-empowered OligoCreator® platform is designed to deliver highly specific, safe, and effective oligonucleotide therapeutics rapidly and reliably," said Konstantin Petropoulos, PhD, Chief Executive Officer of Secarna Pharmaceuticals. "We are excited to collaborate with Curie.Bio, and their portfolio company who share our vision for transforming scientific innovation into life-changing therapies. Start-up companies often have exceptional target or disease expertise but lack the platform technology or infrastructure to quickly discover and develop best-in-class drug products. Together – by combining the best of both worlds with tailored approaches and leveraging Curie.Bio’s expertise in drug discovery and development – we aim to unlock new possibilities for patients suffering from diseases that are difficult to treat with conventional approaches." About Curie.Bio Contact Konstantin Petropoulos, PhD, MBA For media inquiries contact Lydia Robinson-Garcia Email: secarna@mc-services.eu
12.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2135374 12.05.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.